Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Head & Neck 2Gynecologic 2Breast 2Sarcoma 1Dermatologic 1CNS 1

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1

Interventions

Paclitaxel 575Carboplatin 521Cisplatin 351Bevacizumab 252pembrolizumab 228Gemcitabine 157Topotecan 128Cyclophosphamide 128liposomal doxorubicin 127olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 81niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 57Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Tissue Banks × Gynecologic × Clear all
NCT00298064 2023-07-05

Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer

University of New Mexico

Phase NA Withdrawn
Gynecologic

Uterine Cervical Neoplasms

NCT02441140 2020-05-04

Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis

Dana-Farber Cancer Institute

Phase NA Terminated
5 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡